R&G PharmaStudies Co. Ltd. A (301333) — Cash Flow Quality Index
R&G PharmaStudies Co. Ltd. A (301333) has a Cash Flow Quality Index of 1.19x as of June 2022. Operating cash flow of CN¥40.98 Million exceeds net income of CN¥34.56 Million, indicating high earnings quality where cash backs reported profits. Also explore R&G PharmaStudies Co. Ltd. A balance sheet assets for the complete picture of this company's asset base.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
R&G PharmaStudies Co. Ltd. A Cash Flow Quality Index (2019–2025)
Historical Cash Flow Quality Index for R&G PharmaStudies Co. Ltd. A across 7 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check how tangible is R&G PharmaStudies Co. Ltd. A's equity to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for R&G PharmaStudies Co. Ltd. A (2019–2025)
Year-by-year earnings quality comparison for R&G PharmaStudies Co. Ltd. A. For live market cap and the full company financial profile, see market cap of R&G PharmaStudies Co. Ltd. A.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.83x | CN¥114.20 Million | CN¥136.90 Million | ▼ -24.4% |
| 2024 | 1.10x | CN¥154.76 Million | CN¥140.22 Million | ▼ -6.8% |
| 2023 | 1.18x | CN¥192.56 Million | CN¥162.53 Million | ▲ +3.2% |
| 2022 | 1.15x | CN¥130.47 Million | CN¥113.59 Million | ▼ -0.5% |
| 2021 | 1.15x | CN¥114.57 Million | CN¥99.24 Million | ▲ +119.5% |
| 2020 | 0.53x | CN¥44.10 Million | CN¥83.84 Million | ▼ -58.0% |
| 2019 | 1.25x | CN¥103.48 Million | CN¥82.63 Million | — |